Search - tctmd.com

Displaying 21 - 40 of 238

Sort: Relevancy | Date

Podcast Rox Heart Radio

Rox Heart Radio: What's Ahead at ESC 2022

August 17, 2022

Presentation TCT 2021

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

Presenter: Stephan Windecker

November 05, 2021

Podcast Rox Heart Radio

Rox Heart Radio: Lessons From ESC 2021

September 15, 2021

News Conference News ESC 2021

TOMAHAWK: Swift Angiography No Benefit in OHCA Without STEMI

Shelley Wood

August 29, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

Caitlin E. Cox

August 30, 2020

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

News Conference News TVT 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Michael O'Riordan

June 21, 2020

Podcast TCTMD Talking Points

Onyx ONE: Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

April 15, 2020

Presentation TCT 2019

SELUTION SLR: A Sustained Limus Release Drug-Eluting Balloon — First Human Data From a Multicenter Coronary Trial

Presenter: Stephan Windecker

September 27, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

The High-Bleeding Risk Patient: Current Recommendations and Overview of Dedicated Trials

Presenter: Stephan Windecker

September 26, 2019

Opening Debate: Which Metallic DES Should Be on My Cath Lab Shelf? - Choose Whatever You Want! Most Contemporary DES Display Comparable Clinical Performance!

Presentation TCT 2019

Choose Whatever You Want! Most Contemporary DES Display Comparable Clinical Performance!

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Has TAVR Become the Default Therapy in Patients With Severe Aortic Stenosis?

Presenter: Stephan Windecker

September 25, 2019

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

Advertisement

Rox Heart Radio: What's Ahead at ESC 2022

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

Rox Heart Radio: Lessons From ESC 2021

TOMAHAWK: Swift Angiography No Benefit in OHCA Without STEMI

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Trimetazidine Safe but Not Protective Long-term After PCI

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Onyx ONE: Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

SELUTION SLR: A Sustained Limus Release Drug-Eluting Balloon — First Human Data From a Multicenter Coronary Trial

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

The High-Bleeding Risk Patient: Current Recommendations and Overview of Dedicated Trials

Choose Whatever You Want! Most Contemporary DES Display Comparable Clinical Performance!

Has TAVR Become the Default Therapy in Patients With Severe Aortic Stenosis?

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content